General MedicationsOPHTHALMICGeneric
LIVOSTIN
LEVOCABASTINE HYDROCHLORIDE
Standard Dose
EQ 0.05% BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview LIVOSTIN is listed in Drugs@FDA under application 020219 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient LEVOCABASTINE HYDROCHLORIDE Form and strength SUSPENSION/DROPS;OPHTHALMIC - EQ 0.05% BASE Sponsor NOVARTIS Submission history Latest submission status date: 2000-12-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview LIVOSTIN is listed in Drugs@FDA under application 020219 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient LEVOCABASTINE HYDROCHLORIDE Form and strength SUSPENSION/DROPS;OPHTHALMIC - EQ 0.05% BASE Sponsor NOVARTIS Submission history Latest submission status date: 2000-12-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.